Ionis PharmaceuticalsIONS
IONS
About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Employees: 927
0
Funds holding %
of 6,815 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
53% more call options, than puts
Call options by funds: $38M | Put options by funds: $24.8M
18% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 108
0% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 52
0.5% less ownership
Funds ownership: 99.46% [Q2] → 98.97% (-0.5%) [Q3]
2% less funds holding
Funds holding: 353 [Q2] → 347 (-6) [Q3]
10% less capital invested
Capital invested by funds: $6.92B [Q2] → $6.24B (-$675M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 3 (-3) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
84%
upside
Avg. target
$66
103%
upside
High target
$77
136%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Joseph Stringer 23% 1-year accuracy 30 / 128 met price target | 84%upside $60 | Buy Maintained | 20 Dec 2024 |
Piper Sandler Allison Bratzel 73% 1-year accuracy 8 / 11 met price target | 90%upside $62 | Overweight Maintained | 14 Nov 2024 |
Wells Fargo Yanan Zhu 6% 1-year accuracy 1 / 16 met price target | 136%upside $77 | Overweight Maintained | 7 Nov 2024 |
Financial journalist opinion
Based on 7 articles about IONS published over the past 30 days
Neutral
PRNewsWire
1 day ago
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
– Accelerating value creation with numerous commercial, regulatory and pipeline milestones – – Ionis outlines clear path to sustained positive cash flow – CARLSBAD, Calif. , Jan. 13, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2024 achievements and previewed important milestones expected in 2025.
Neutral
PRNewsWire
6 days ago
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif. , Jan. 8, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P.
Positive
Seeking Alpha
3 weeks ago
Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of Tryngolza for FCS positions Ionis as the first company to independently develop and launch an RNA-targeted therapy. Ionis forecasts that its pipeline, containing approximately 40 investigational drugs, could generate billions in peak sales, with four launches projected in the next three years.
Positive
Zacks Investment Research
3 weeks ago
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval.
Positive
Benzinga
3 weeks ago
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.'s IONS Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can lead to acute pancreatitis (AP).
Neutral
PRNewsWire
3 weeks ago
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease Indicated for adults with FCS regardless of genetically or clinically confirmed diagnosis TRYNGOLZA is the first of four independent launches planned over the next three years, pending approvals Ionis to host webcast today at 6:45pm ET CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP).
Positive
Reuters
3 weeks ago
US FDA approves Ionis Pharma's genetic disorder drug
The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed on Thursday.
Positive
Zacks Investment Research
1 month ago
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
The mean of analysts' price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
1 month ago
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
Ionis Pharmaceuticals (IONS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Zacks Investment Research
1 month ago
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
Ionis Pharmaceuticals (IONS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Charts implemented using Lightweight Charts™